4d Molecular Therapeutics Inc (FDMT)

$25.34

-0.3

(-1.17%)

Market is closed - opens 7 PM, 20 May 2024

Insights on 4d Molecular Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, -19.0K → 28.0K (in $), with an average increase of 167.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -10.25M → -32.40M (in $), with an average decrease of 107.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 54.7% return, outperforming this stock by 14.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 226.3% return, outperforming this stock by 234.0%

Performance

  • $24.36
    $25.65
    $25.34
    downward going graph

    3.87%

    Downside

    Day's Volatility :5.03%

    Upside

    1.21%

    downward going graph
  • $9.44
    $36.25
    $25.34
    downward going graph

    62.75%

    Downside

    52 Weeks Volatility :73.96%

    Upside

    30.1%

    downward going graph

Returns

Period4d Molecular Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-7.48%
0.8%
0.0%
6 Months
104.52%
13.4%
0.0%
1 Year
38.24%
11.4%
0.0%
3 Years
-7.72%
17.7%
-19.9%

Highlights

Market Capitalization
1.3B
Book Value
$11.74
Earnings Per Share (EPS)
-2.36
Wall Street Target Price
52.3
Profit Margin
0.0%
Operating Margin TTM
-136200.0%
Return On Assets TTM
-17.29%
Return On Equity TTM
-25.53%
Revenue TTM
20.5M
Revenue Per Share TTM
0.47
Quarterly Revenue Growth YOY
-90.60000000000001%
Gross Profit TTM
-77.1M
EBITDA
-116.5M
Diluted Eps TTM
-2.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.0
EPS Estimate Next Year
-3.36
EPS Estimate Current Quarter
-0.74
EPS Estimate Next Quarter
-0.73

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for 4d Molecular Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
11
12
Hold
1
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 106.39%

Current $25.34
Target $52.30

Company Financials

FY18Y/Y Change
Revenue
14.1M
↑ 144.04%
Net Income
-9.6M
↓ 14.9%
Net Profit Margin
-67.59%
↑ 126.24%
FY19Y/Y Change
Revenue
7.0M
↓ 50.56%
Net Income
-52.9M
↑ 454.28%
Net Profit Margin
-757.79%
↓ 690.2%
FY20Y/Y Change
Revenue
13.6M
↑ 94.85%
Net Income
-56.5M
↑ 6.8%
Net Profit Margin
-415.38%
↑ 342.41%
FY21Y/Y Change
Revenue
18.0M
↑ 32.52%
Net Income
-68.3M
↑ 20.79%
Net Profit Margin
-378.63%
↑ 36.75%
FY22Y/Y Change
Revenue
3.1M
↓ 82.65%
Net Income
-101.1M
↑ 47.99%
Net Profit Margin
-3.2K%
↓ 2851.67%
FY23Y/Y Change
Revenue
20.7M
↑ 562.29%
Net Income
-100.8M
↓ 0.24%
Net Profit Margin
-486.59%
↑ 2743.71%
Q4 FY22Q/Q Change
Revenue
1.2M
↑ 149.4%
Net Income
-27.3M
↑ 13.2%
Net Profit Margin
-2.2K%
↑ 2631.31%
Q1 FY23Q/Q Change
Revenue
298.0K
↓ 76.1%
Net Income
-27.3M
↓ 0.05%
Net Profit Margin
-9.1K%
↓ 6959.89%
Q2 FY23Q/Q Change
Revenue
239.0K
↓ 19.8%
Net Income
-29.6M
↑ 8.65%
Net Profit Margin
-12.4K%
↓ 3244.65%
Q3 FY23Q/Q Change
Revenue
20.2M
↑ 8353.56%
Net Income
-10.3M
↓ 65.37%
Net Profit Margin
-50.76%
↑ 12340.87%
Q4 FY23Q/Q Change
Revenue
-19.0K
↓ 100.09%
Net Income
-32.3M
↑ 214.77%
Net Profit Margin
169.9K%
↑ 169961.29%
Q1 FY24Q/Q Change
Revenue
28.0K
↓ 247.37%
Net Income
-32.4M
↑ 0.37%
Net Profit Margin
-115.7K%
↓ 285628.39%
FY18Y/Y Change
Total Assets
97.0M
↑ 254.94%
Total Liabilities
124.6M
↑ 165.52%
FY19Y/Y Change
Total Assets
58.2M
↓ 39.95%
Total Liabilities
131.2M
↑ 5.34%
FY20Y/Y Change
Total Assets
288.3M
↑ 395.12%
Total Liabilities
31.9M
↓ 75.65%
FY21Y/Y Change
Total Assets
353.5M
↑ 22.6%
Total Liabilities
560.5M
↑ 1654.58%
FY22Y/Y Change
Total Assets
261.8M
↓ 25.92%
Total Liabilities
30.5M
↓ 94.56%
FY23Y/Y Change
Total Assets
339.9M
↑ 29.81%
Total Liabilities
32.1M
↑ 5.09%
Q4 FY22Q/Q Change
Total Assets
261.8M
↓ 6.54%
Total Liabilities
30.5M
↑ 6.23%
Q1 FY23Q/Q Change
Total Assets
244.0M
↓ 6.81%
Total Liabilities
25.4M
↓ 16.7%
Q2 FY23Q/Q Change
Total Assets
352.5M
↑ 44.46%
Total Liabilities
725.3M
↑ 2753.79%
Q3 FY23Q/Q Change
Total Assets
361.6M
↑ 2.58%
Total Liabilities
31.7M
↓ 95.63%
Q4 FY23Q/Q Change
Total Assets
339.9M
↓ 6.01%
Total Liabilities
32.1M
↑ 1.21%
Q1 FY24Q/Q Change
Total Assets
629.9M
↑ 85.32%
Total Liabilities
29.3M
↓ 8.54%
FY18Y/Y Change
Operating Cash Flow
-16.3M
↓ 297.3%
Investing Cash Flow
-414.0K
↓ 105.39%
Financing Cash Flow
84.6M
↑ 528506.25%
FY19Y/Y Change
Operating Cash Flow
-36.7M
↑ 125.89%
Investing Cash Flow
-3.2M
↑ 673.67%
Financing Cash Flow
-2.2M
↓ 102.6%
FY20Y/Y Change
Operating Cash Flow
-50.9M
↑ 38.68%
Investing Cash Flow
-1000.0K
↓ 68.78%
Financing Cash Flow
279.0M
↓ 12809.93%
FY21Y/Y Change
Operating Cash Flow
-69.1M
↑ 35.8%
Investing Cash Flow
-172.7M
↑ 17168.0%
Financing Cash Flow
118.1M
↓ 57.67%
FY22Y/Y Change
Operating Cash Flow
-86.7M
↑ 25.39%
Investing Cash Flow
-17.1M
↓ 90.13%
Financing Cash Flow
3.1M
↓ 97.39%
Q4 FY22Q/Q Change
Operating Cash Flow
-22.2M
↑ 5.7%
Investing Cash Flow
-35.8M
↓ 332.77%
Financing Cash Flow
2.0M
↑ 344.78%
Q1 FY23Q/Q Change
Operating Cash Flow
-27.9M
↑ 25.62%
Investing Cash Flow
43.1M
↓ 220.55%
Financing Cash Flow
11.0M
↑ 437.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-22.1M
↓ 20.93%
Investing Cash Flow
49.3M
↑ 14.28%
Financing Cash Flow
130.5M
↑ 1087.18%

Technicals Summary

Sell

Neutral

Buy

4d Molecular Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
4d Molecular Therapeutics Inc
4d Molecular Therapeutics Inc
-3.98%
104.52%
38.24%
-7.72%
-37.43%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
4d Molecular Therapeutics Inc
4d Molecular Therapeutics Inc
NA
NA
NA
-3.0
-0.26
-0.17
NA
11.74
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
4d Molecular Therapeutics Inc
4d Molecular Therapeutics Inc
Buy
$1.3B
-37.43%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • Viking Global Investors LP

    9.36%
  • RA Capital Management, LLC

    8.14%
  • BlackRock Inc

    6.77%
  • HHG PLC

    6.05%
  • Deep Track Capital, LP

    4.47%
  • Vanguard Group Inc

    3.65%

Corporate Announcements

  • 4d Molecular Therapeutics Inc Earnings

    4d Molecular Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim

Organization
4d Molecular Therapeutics Inc
Employees
171
CEO
Dr. John F. Milligan Ph.D.
Industry
Healthcare

FAQs